BaroFold and Boehringer Ingelheim announce partnership

Boehringer Ingelheim will use BaroFold's PreEMT technology at its Vienna site.

BaroFold and Boehringer Ingelheim have entered into a non-exclusive agreement that will facilitate the development of biologic therapies at the latter's microbial facility in Vienna, Austria.

Under the terms of the agreement, Boehringer Ingelheim will receive a laboratory-scale reactor of BaroFold's Pressure Enabled Manufacturing Technology (PreEMT).

PreEMT uses high pressure to disaggregate and refold recombinant proteins at far greater yield and efficiency rates than other methods, thereby reducing manufacturing costs.

The high pressure protein refolding technology will be used on a variety of proteins under development at the Vienna facility, according to Georg Klima, executive director of process science at Boehringer Ingelheim.

"This collaboration builds upon the exciting work we have completed with BaroFold over the last 18 months and enhances our strategy to integrate the most innovative technologies for biologic manufacturing," he added.

Kyle Lefkoff, chairman of BaroFold, said the company was "very excited" to be licensing its technology to Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacturing.